Buckley Wealth Management LLC Has $6.11 Million Stake in Pfizer Inc. (NYSE:PFE)

Buckley Wealth Management LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 2.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 166,495 shares of the biopharmaceutical company’s stock after purchasing an additional 3,770 shares during the quarter. Pfizer comprises 2.1% of Buckley Wealth Management LLC’s holdings, making the stock its 13th biggest position. Buckley Wealth Management LLC’s holdings in Pfizer were worth $6,107,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. BancFirst Trust & Investment Management grew its holdings in shares of Pfizer by 2.3% during the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 398 shares in the last quarter. Strategic Investment Advisors MI grew its position in Pfizer by 32.1% in the first quarter. Strategic Investment Advisors MI now owns 94,117 shares of the biopharmaceutical company’s stock valued at $3,840,000 after purchasing an additional 22,879 shares in the last quarter. State of Michigan Retirement System increased its stake in Pfizer by 0.9% in the 1st quarter. State of Michigan Retirement System now owns 1,771,584 shares of the biopharmaceutical company’s stock valued at $72,281,000 after buying an additional 15,900 shares during the last quarter. MainStreet Investment Advisors LLC increased its position in shares of Pfizer by 1.6% in the first quarter. MainStreet Investment Advisors LLC now owns 197,477 shares of the biopharmaceutical company’s stock valued at $8,057,000 after acquiring an additional 3,099 shares during the last quarter. Finally, Center For Asset Management LLC boosted its position in Pfizer by 28.0% during the first quarter. Center For Asset Management LLC now owns 23,894 shares of the biopharmaceutical company’s stock valued at $975,000 after purchasing an additional 5,228 shares during the last quarter. 68.05% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of PFE opened at $33.64 on Tuesday. The firm has a market cap of $189.93 billion, a PE ratio of 8.95, a price-to-earnings-growth ratio of 1.14 and a beta of 0.59. Pfizer Inc. has a 52-week low of $33.44 and a 52-week high of $54.93. The business’s 50 day moving average price is $35.80 and its two-hundred day moving average price is $37.96. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.82 and a current ratio of 2.12.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.10. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $13.36 billion. During the same period last year, the company posted $2.04 earnings per share. The business’s quarterly revenue was down 54.1% on a year-over-year basis. On average, equities analysts anticipate that Pfizer Inc. will post 3.33 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th were issued a $0.41 dividend. The ex-dividend date was Thursday, July 27th. This represents a $1.64 annualized dividend and a yield of 4.88%. Pfizer’s payout ratio is currently 43.62%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price objective on shares of Pfizer in a research report on Monday. Barclays dropped their price target on Pfizer from $40.00 to $38.00 in a research note on Tuesday, July 11th. BMO Capital Markets dropped their price objective on shares of Pfizer from $45.00 to $44.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 2nd. Morgan Stanley cut their price objective on shares of Pfizer from $42.00 to $40.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 2nd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $62.00 target price on shares of Pfizer in a research report on Wednesday, September 13th. Twelve investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $46.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.